Evidence map›Paper›PMID 28587418›Full record

ArticleExperimental and therapeutic medicine2017

Synergistic inhibition of leukemia WEHI-3 cell growth by arsenic trioxide and

Yu-Jui Kuo, Yan-Jin Liu, Tzong-Der Way, Su-Yin Chiang, Jaung-Geng Lin, Jing-Gung Chung

RetractedOpen access · diamondAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Effect of arsenic trioxide on cervical cancer and its mechanisms.Experimental and therapeutic medicine · 2020
    Article
  5. The Antitumor Constituents from Hedyotis Diffusa Willd.Molecules (Basel, Switzerland) · 2017
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yu-Jui KuoGraduate Institute of Chinese Medicine, China Medical University, Taichung 40402, Taiwan, R.O.C.
Yan-Jin LiuGraduate Institute of Pharmaceutical Chemistry, College of Pharmacy, China Medical University, Taichung 40402, Taiwan, R.O.C.
Tzong-Der WayDepartment of Biological Sciences and Technology, College of Biopharmaceutical and Food Sciences, China Medical University, Taichung 40402, Taiwan, R.O.C.
Su-Yin ChiangDepartment of Health and Nutrition Biotechnology, College of Health Science, Asia University, Taichung 41354, Taiwan, R.O.C.
Jaung-Geng LinGraduate Institute of Chinese Medicine, China Medical University, Taichung 40402, Taiwan, R.O.C.
Jing-Gung ChungDepartment of Biological Sciences and Technology, College of Biopharmaceutical and Food Sciences, China Medical University, Taichung 40402, Taiwan, R.O.C.
China Medical University · TWAsia University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arsenic trioxide (ATO) is clinically used to treat acute promyelocytic leukemia (APL); however, the therapeutic dose of ATO may prompt critical cardiac side effects. Combination therapy may be used to improve the therapeutic efficiency. To evaluate this possibility, the present study determined the combined effects of

Indexed as

acute promyelocytic leukemiaapoptosisarsenic trioxidedeath receptorHedyotis diffusa Willd

Identifiers

PMID28587418
PMCPMC5450767
OpenAlexW2608019141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.